tetano
Editor, Senior Moderator
High Blood Press Cardiovasc Prev
. 2022 Jan 3.
doi: 10.1007/s40292-021-00502-5. Online ahead of print.
Humoral Immune Response to COVID-19 Vaccination in Hemodialysis Patients: A Retrospective, Observational Case-Control Pilot Study
Luca Piscitani[SUP] 1 [/SUP], Rita Del Pinto[SUP] 2 [/SUP], Andrea Basili[SUP] 3 [/SUP], Marilena Tunno[SUP] 3 [/SUP], Claudio Ferri[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus 2 disease is associated with increased mortality and morbidity in chronic hemodialysis patients METHODS: A retrospective, observational case-control pilot study was conducted on consecutive hemodialysis outpatients (cases) and control group of individuals with preserved renal function. Complete SARS-CoV-2 vaccination with BNT162b2 mRNA vaccine, followed by determination of serum antibodies after the second dose, were required from participants in both groups. Previous COVID-19 was an exclusion criterium.
Results: 21 hemodialysis patients (M:F = 13:8, mean age 67.5 ± 13.4) and 16 controls without chronic kidney disease (M:F = 4:12, mean age 46.8 ± 12.7) were included. Hemodialysis patients had lower mean titers of serum antibodies to the SARS-CoV-2 spike antigen compared with controls (492.39 vs 1901.20 IU/mL, respectively; p < 0.001), a finding that was confirmed in the age-matched analysis on 18 participants (580.8 vs 1836.4 IU/mL, p = 0.006).
Conclusions: This study supports the finding of hyporesponsiveness to mRNA vaccination among hemodialysis patients.
Keywords: Antibody activity; COVID-19; Hemodialysis; mRNA vaccines.
. 2022 Jan 3.
doi: 10.1007/s40292-021-00502-5. Online ahead of print.
Humoral Immune Response to COVID-19 Vaccination in Hemodialysis Patients: A Retrospective, Observational Case-Control Pilot Study
Luca Piscitani[SUP] 1 [/SUP], Rita Del Pinto[SUP] 2 [/SUP], Andrea Basili[SUP] 3 [/SUP], Marilena Tunno[SUP] 3 [/SUP], Claudio Ferri[SUP] 2 [/SUP]
Affiliations
- PMID: 34978702
- DOI: 10.1007/s40292-021-00502-5
Abstract
Introduction: Coronavirus 2 disease is associated with increased mortality and morbidity in chronic hemodialysis patients METHODS: A retrospective, observational case-control pilot study was conducted on consecutive hemodialysis outpatients (cases) and control group of individuals with preserved renal function. Complete SARS-CoV-2 vaccination with BNT162b2 mRNA vaccine, followed by determination of serum antibodies after the second dose, were required from participants in both groups. Previous COVID-19 was an exclusion criterium.
Results: 21 hemodialysis patients (M:F = 13:8, mean age 67.5 ± 13.4) and 16 controls without chronic kidney disease (M:F = 4:12, mean age 46.8 ± 12.7) were included. Hemodialysis patients had lower mean titers of serum antibodies to the SARS-CoV-2 spike antigen compared with controls (492.39 vs 1901.20 IU/mL, respectively; p < 0.001), a finding that was confirmed in the age-matched analysis on 18 participants (580.8 vs 1836.4 IU/mL, p = 0.006).
Conclusions: This study supports the finding of hyporesponsiveness to mRNA vaccination among hemodialysis patients.
Keywords: Antibody activity; COVID-19; Hemodialysis; mRNA vaccines.